Padded coffers

It's still early days for Atlas Venture's first life sciences-only fund, but don't be surprised if the firm starts putting more money to work with smaller syndicates. Atlas wants to make sure it has an even bigger stake to multiply in the next exit than the firm just reaped from Padlock Therapeutics Inc.

Last week, Bristol-Myers Squibb Co. (NYSE:BMY) announced plans to acquire Padlock for $225 million in upfront and near-term milestone payments and $375 million in development and regulatory milestones...